200572-35-6

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, 1,1-dimethylethyl ester, (3S,4R)-
• CAS NO: 200572-35-6
• Molecular Formula: C24H28FNO5
• Molecular Weight: 429.488
• Mol File: 200572-35-6.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, 1,1-dimethylethyl ester, (3S,4R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, 1,1-dimethylethyl ester, (3S,4R)-(200572-35-6)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, 1,1-dimethylethyl ester, (3S,4R)-(200572-35-6)

Safety Data

• Hazardous Substances Data: 200572-35-6(Hazardous Substances Data)

Upstream product

• 349446-96-4 {(3S,4R)-4-(p-fluorophenyl)-3-(hydroxymethyl)-1-[1-(S)-phenylethyl]}piperidine 
• 352-13-6 4-flourophenylmagnesium bromide 
• 200572-34-5 (3S,4R)-tert-butyl 4-(4-fluorophenyl)-3-(((methylsulfonyl)oxy)methyl)piperidine-1-carboxylate 
• 277744-08-8 (3S,4R)-4-(p-fluorophenyl)-1-[(1R)-2-hydroxy-1-phenylethyl]-3-piperidinemethanol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 200572-39-0 (+/-)-cis,trans-4-(4-fluorophenyl)-5-methoxycarbonylpiperidin-2-one 
• 200572-36-7 dimethyl 2-cyano-3-(4-fluorophenyl)glutarate 
• 96426-60-7 methyl (2E)-3-(4-fluorophenyl)-2-propenoate 
• 459-57-4 4-fluorobenzaldehyde 
• 1026805-86-6 (3S,4S)-[3-(4-fluoro-phenyl)-5-nitro-4-triisopropylsilanyloxymethyl-pent-1-enyl]-(4-methoxy-phenyl)-carbamic acid tert-butyl ester 

Downstream Products

• 110429-35-1 (-)-paroxetine hydrochloride 
• 115-11-7 isobutene 
• 61869-08-7 paroxetine 
• 61869-08-7 paroxetine 

Relevant articles and documents

Diastereoconvergent Synthesis of (–)-Paroxetine

A diastereoconvergent approach to (–)-paroxetine from diastereomeric 3,4-epoxy-2-piperidones is reported. For this synthesis, a regioselective and stereodivergent CuI-catalyzed epoxide-ring-opening reaction of epoxyamide precursors to give the 4-(4-fluorophenyl)-2-piperidone skeleton with the correct absolute configuration is crucial. Using CuBr·SMe2 as a catalyst, the epoxide-ring-opening reaction takes place with inversion of configuration; the configuration is retained when CuI is used.

Enantioselective Michael additions to α,β-unsaturated imides catalyzed by a salen-al complex

(Salen)aluminum complex 1b is an efficient catalyst for the conjugate addition of di- and trisubstituted nitriles to a wide range of acyclic alkyl- and aryl-substituted α,β-unsaturated imides. This new methodology provides access to multifunctional compounds that previously have not been readily accessible in enantioenriched form. Synthetic applications of these products include the preparation of enantiomerically enriched piperidines, as exemplified by an expedient asymmetric catalytic synthesis of (-)-paroxetine. Copyright

Improved synthesis of paroxetine hydrochloride propan-2-ol solvate through one of metabolites in humans, and characterization of the solvate crystals

Paroxetine, a potent and selective inhibitor of 5-hydroxytryptamine (serotonin) uptake, was prepared through a piperidine derivative, which was reported to be one of the paroxetine metabolites in humans. Thus, the piperidine derivative was converted to its N-tert-butoxycarbonyl (N-Boc) derivative, which was then converted to N-Boc paroxetine. Paroxetine hydrochloride propan-2-ol (isopropyl alcohol (IPA)) solvate crystals were directly obtained from the N-Boc paroxetine by adding hydrogen chloride to the N-Boc paroxetine IPA solution. The amount of IPA content in the crystals was reduced by drying with a continuous change of powder X-ray diffraction patterns. Other characterizations of the solvate crystals were also conducted.